Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04650282
Other study ID # HUM00185200
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date March 18, 2021
Est. completion date April 6, 2021

Study information

Verified date August 2022
Source University of Michigan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial will enroll participants to evaluate the effects of SPG block on post-traumatic headache. The study hypothesizes that patients that receive a SPG block with lidocaine vs. placebo (saline) will have a lower number of headache days in the week following the procedure, and will also report lower symptom scores. Eligible participants will receive one treatment (SPG block) as well as complete surveys prior to and after receiving treatment (for a total of approximately 2 weeks).


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date April 6, 2021
Est. primary completion date April 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Diagnosed with a concussion and are greater than 14 days from the date of their injury. - Experiencing greater or equal than 4 occurrences of headache per week lasting at least 1 hour per occurrence with a headache severity score greater or equal to 2 out of 6. Exclusion Criteria: - Allergy to local anesthetics of the amide type (for example (i.e.) lidocaine) - Frequent epistaxis (i.e. more than one nose bleed per month), - Bleeding disorders - History of any of the following: nasal or facial fracture, nasal septal defect, any other craniofacial abnormality, hepatic disease, Adam-Stokes syndrome, Wolff-Parkinson-White syndrome, or severe degrees of sinoatrial, atrioventricular, or intraventricular heart block - Pregnant - Are at increased risk for methemoglobinemia (including patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, and concurrent exposure to oxidizing agents or their metabolites and drugs associated with methemoglobinemia)

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Lidocaine in SphenoCath device
Participants will receive 2.5 cc of lidocaine 1% solution intranasally via a SphenoCath device into each nares.The portion of the procedure involving this device lasts approximately 30-60 seconds.
Saline Solution in SphenoCath device
Participants will receive saline solution via a SphenoCath device into each nares. The portion of the procedure involving this device lasts approximately 30-60 seconds.

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan

Sponsors (1)

Lead Sponsor Collaborator
University of Michigan

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Change in Headache Severity Score Patients will rate their headache on a scale of 0 to 6, with 0 corresponding to "absent" and 6 corresponding to "severe." 48 hours pre-SPG to 48 hours after SPG block
Secondary Patient Global Impression of Change (PGIC) A rating scale of global improvement which participants use a seven-point scale ("1" = very much improved, "4" = no change, "7" very much worse). Participants will rate their change at two hours and 24 hours following the SPG block procedure. 2, 24 hours after SPG block
Secondary Mean Change in the Number of Headache Occurrences The number of headache episodes over the one week prior to the SPG block compared to one week after the procedure. 1 week before SPG block, up to 1 week post SPG block
Secondary Mean Headache Occurrences Within 48 Hours pre-and 48 Hours Post-SPG Block The number of headache episodes prior to the SPG block to after the procedure. 48 hours pre SPG to 48 hours post block
Secondary Mean Headache Occurrences Within 1 Week Pre- and 1 Week Post-SPG Block The number of headache episodes over the one week prior to the SPG block to one week after the procedure. 1 week before SPG block up to 1 week post SPG block
Secondary Mean Change in Headache Hours Per Day The number hours with headache 1 week prior to the SPG block and for up to 1 week after the procedure. 1 week before SPG block, up to 1 week post SPG block
Secondary Mean Headache Hours Per Day Within 48 Hours Pre- and 48 Hours Post-SPG Block 48 hours pre SPG up to 48 hours post SPG
Secondary Mean Headache Hours Per Day Within 1 Week Pre and 1 Week Post Block 1 week before SPG block to 1 week post SPG block
Secondary Mean Change in the Number of Days With Headache 1 week before SPG block, up to 1 week post SPG
Secondary Mean Number of Days With Headache in the1 Week Post-SPG Block Compared to 1 Week Pre-SPG Block. 1 week before SPG block up to 1 week post SPG
Secondary Mean Change in As-needed Headache Treatment Uses Patients will be asked to report the number of uses of as-needed headache medications used in the one week prior to the SPG block and after SPG block for up to one week after the procedure. 1 week before SPG block to 1 week post SPG block
Secondary Mean As-needed Headache Treatment Uses Within 48 Hours Pre- and 48 Hours Post-SPG Patients will be asked to report the number of uses of as-needed headache medications used in the one week prior to the SPG block and after SPG block for up to one week after the procedure. 48 hours before SPG block to 48 hours post SPG block
Secondary Mean As-needed Headache Treatment Uses Within 1 Week Pre and 1 Week Post Block Patients will be asked to report the number of uses of as-needed headache medications used in the one week prior to the SPG block and after SPG block for up to one week after the procedure. 1 week before SPG block up to 1 week post SPG block
See also
  Status Clinical Trial Phase
Terminated NCT03472872 - A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache Phase 4
Withdrawn NCT05410366 - Safe Harbors in Emergency Medicine, Specific Aim 3
Withdrawn NCT02866084 - Neuromodulation Treatment of Vestibular Migraines N/A
Active, not recruiting NCT03537573 - Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care N/A
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Not yet recruiting NCT04352218 - Safety Profile of PETALO CVS in the Treatment of Non-thrombotic Internal Jugular Vein Stenosis and Chronic Headache Phase 2
Completed NCT02734992 - Acceptance and Commitment Therapy vs Medical Treatment as Usual Wait-list Control for Primary Headache Sufferers N/A
Completed NCT01327118 - Prostaglandin F2alpha in a Human Headache Model N/A
Completed NCT01153789 - Study of Oculomotor Dysfunction Leading to Children Vertigo N/A
Not yet recruiting NCT00969995 - Identification of Inflammatory Markers in Migraine Patients N/A
Not yet recruiting NCT00752921 - Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache Phase 4
Completed NCT00212810 - Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache. Phase 4
Terminated NCT00291395 - PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers Phase 1
Completed NCT00263094 - An End to the Yom Kippur (and Ramadan) Headache N/A
Completed NCT00135122 - Prednisolone in the Treatment of Withdrawal Headache in Probable Medication Overuse Headache Phase 3
Completed NCT02475005 - An Intervention to Improve Adolescent Headache Self-management N/A
Completed NCT03163901 - The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury N/A
Completed NCT01664585 - Exercise Training With Physically Active Lifestyle to Reduce Headache and Quality of Life N/A
Completed NCT04632420 - Evaluation of Headache and Childbirth in a Chronic Pain Population
Recruiting NCT05033613 - Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease